Disease Landscape and Forecast Insights

Acute heart failure (AHF) is one of the leading causes of hospitalization in the United States, representing a significant healthcare burden. AHF patients experience high rates of mortality and…

Renal anemia is a common complication of chronic kidney disease (CKD). Although treatment options exist for renal anemia, physicians, patients, and healthcare systems are concerned over some…

Biomarker-targeted therapies are distinguished from other oncology drugs in that they are accompanied by a diagnostic test that can identify a specific patient type most likely to benefit from…

The wet age-related macular degeneration (AMD) market in the United States is unique given that the key approved therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea, and Novartis’s…

A patient with major depressive disorder (MDD) who does not achieve adequate response to more than two different trials of antidepressant drugs is then usually considered as having treatment-…

The type 2 diabetes market has become increasingly crowded, with therapies competing over preferential formulary placement as well as patient share. Using primary research from U.S…

Although several effective anti-inflammatory agents and bronchodilators are available to control disease in mild-to-moderate asthmatics, great unmet need exists in the treatment of severe disease…

Chronic kidney disease (CKD) is a general term for a set of heterogeneous disorders that negatively affect the function and structure of the kidney. Because of the role of the kidney in many of the…

Market Outlook The expedited approvals of Novartis’s Kymriah for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (ALL), and…

Obesity is arguably the most pressing public health issue in the United States. Prevalence of obesity is extremely high, and its chronic progression is associated with type 2 diabetes and adverse…

Systemic lupus erythematosus (SLE) is a complex disease characterized by distinct manifestations. Currently, most treatments available to treat SLE are used off-label. The approval of Benlysta in…

Recent launches of Celltrion’s Truxima (rituximab) and Sandoz’s Rixathon (rituximab) have expanded the biosimilar sector of the European oncology market. In the United States, only a single…